Valuation check: VRCA's profit margin is -102.84%, below the Healthcare sector average of 21.34%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Verrica Pharmaceuticals (VRCA) currently reports a profit margin of -102.84% as of June 2026. That compares with -332.42% in the prior-year period — up 69.1% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Verrica Pharmaceuticals's profit margin history and peer comparisons.
Verrica Pharmaceuticals's profit margin increased from -332.42% to -102.84% — a 69.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Verrica Pharmaceuticals's profit margin of -102.84% is lower than the Healthcare sector average of 21.34%. That is roughly 582.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Verrica Pharmaceuticals's current -102.84% should be judged against Healthcare norms (sector average: 21.34%) and against VRCA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -102.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Verrica Pharmaceuticals, and consider following VRCA for alerts when major investors trade the stock.